Bond Screener
Regeneron
LEI 549300RCBFWIRX3HYQ56
Organization name
Regeneron Pharmaceuticals Inc
Country name
USA
Country of registration
USA
Industry
Pharmaceutical Preparation and Biotechnology
Credit Ratings
in foreign currency
Public debt
2,000 mln USD
Upgrade to Premium features
Cbonds consolidates global bond, stock, ETF and indices data into a single platform — so you can analyze faster, make informed investment decisions and outperform the market
Get access
-
Full access to the largest bond database
Bond parameters,
prospectuses -
Seamless
Data exportAnalyze the data in the most efficient way
-
Bond pricing
Current & historical quotes from 400+ stock exchanges & OTC market
-
Smart risk assessment
Credit ratings, financial reports
Trading Schedule Issuer map
Quotes
/
/
/
pcs.
pcs.
pcs.
- «
- 1
- ...
- {{ quotes.page - 2 }}
- {{ quotes.page - 1 }}
- {{ quotes.page }}
- {{ quotes.page + 1 }}
- {{ quotes.page + 2 }}
- ...
- {{ quotesLastPage }}
- »
Quotes provided by information providers are indicative in nature
Profile
|
Regeneron Pharmaceuticals, Inc. (Regeneron) is an integrated biopharmaceutical company, which discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. As of December 31, 2011, the Company had two marketed products: EYLEA (aflibercept) Injection and ARCALYST (rilonacept) Injection for Subcutaneous Use. As of December 31, 2011, the Company had 13 product candidates in clinical development. Its Trap-based, late-stage programs are EYLEA, which is being developed for the treatment of additional serious eye diseases; ZALTRAP (aflibercept), known in the scientific literature as vascular endothelial growth factor (VEGF) trap, which is being developed in oncology in collaboration with Sanofi; and ARCALYST, which is being developed for the prevention of gout flares in patients initiating uric acid-lowering treatment.
|
General information
-
Organization nameRegeneron Pharmaceuticals Inc
-
Organization statusOperating organization
-
Address777 Old Saw Mill River Road Tarrytown, USA, 10591
-
Site
News
IFRS/US GAAP reports
| 2026 | |
| 2025 | |
| 2024 | |
| 2023 | |
| 2022 | |
| 2021 | |
| 2020 | |
| 2019 | |
| 2018 | |
| 2017 | |
| 2016 | |
| 2015 | |
| 2014 | |
Show all
Hide
Authorization required
You need to request access
Stocks
General information
-
Organization nameRegeneron Pharmaceuticals Inc
-
Organization statusOperating organization
-
Address777 Old Saw Mill River Road Tarrytown, USA, 10591
-
Site
Codes
-
LEI549300RCBFWIRX3HYQ56
-
SIC2834 PHARMACEUTICAL PREPARATIONS
-
NACE*** ***
-
NAICS*** ***
-
CIK0000872589
-
EIN13-3444607
